Axon generated potential therapeutic antibodies that are able to neutralize the SARS-CoV-2 virus
In cooperation with the Virological Institute of Biomedical Research Center at the Slovak Academy of Sciences in Bratislava, Axon successfully tested the efficacy of these therapeutic antibodies on the live SARS-CoV-2 virus
Axon has begun preparing these potential therapeutic antibodies for the humanisation process, which is required to start human clinical trials

BRATISLAVA, SOLVAKIA / ACCESSWIRE / November 25, 2020 / AXON Neuroscience ("Axon"), a clinical-stage biotech company and a world leader in the development of tau vaccines for therapy and prevention against Alzheimer's Disease, announced today that it successfully tested therapeutic antibodies on the live SARS-CoV-2 virus.

Axon generated these antibodies, which can prevent the SARS-CoV-2 virus from reproducing, in the course of developing its prophylactic COVID-19 vaccine ACvac1 ("COVIDAX"). Using antibodies that demonstrated strong efficacy in several independent tests, Axon was able to map the most vulnerable parts of the virus, which are then detectible by the human immune system.

Norbert Žilka, the Chief Scientific Officer of Axon, said: "Some of these antibodies were able to completely eliminate the virus, showing their therapeutic potential. We have subsequently demonstrated their efficacy in a number of other conceptually different tests that we have developed in our laboratories. We will now focus on the process of humanisation, in order to start the production process, which is necessary to begin the clinical trials."

Michal Fresser, CEO of Axon, added: "Axon's research program is based on 20+ years of innovative, and at times seemingly unconventional, research and development that has led to major breakthroughs. We are delighted to announce that we have successfully identified antibodies with a potential therapeutic effect in patients diagnosed with COVID-19. We have a two-pronged goal: to continue developing our preventive COVIDAX vaccine to immunize vulnerable populations; and, in parallel, to develop a drug that can halt and mitigate the COVID-19 virus in those infected. This would have the potential to flatten the curve and take pressure off overburdened health care systems. We have decided to open the project to interested investors through crowdfunding (www.covidax.eu) because we would like to stay independent and continue our research program unaffected by political or industry pressure."

ACmab1 (COVIMAX) – neutralising antibodies against COVID-19

ACmab1 is a therapeutic candidate intended to treat those infected with COVID-19. The antibodies show the ability to target vulnerable parts of the S-protein of the virus, in order to stop the virus from interacting with host cells and replicating.

Testing the antibodies was done at the laboratories of the Virological Institute of Biomedical Research Center at the Slovak Academy of Sciences in Bratislava. The efficacy of the selected antibody candidates was tested directly on the live SARS-CoV-2 virus on cell cultures. Results from these tests show that the antibodies are able to efficiently stop the interaction of virus with the host cell and stop its further reproduction.

RNDr. Boris Klempa, DrSc, Virological Institute, BMC of SAS added: "In our cooperation with Axon, we are utilising the plaque-reduction neutralization test. This test is performed in our specialized laboratory compliant with a 3rd degree of Biosafety Level requirements ("BSL3"), as we are working directly with the infectious virus SARS-CoV-2 (in the form of our isolate BMC5). Tests are being performed in a strictly blinded mode; our team receives only numbered samples, which we then evaluate based on their ability to neutralize the virus. We have identified a strongly neutralizing ability in several of these blinded samples."

About Axon Neuroscience

Axon Neuroscience is an industry leading, clinical stage biotech company and an innovator in the development of peptide vaccines against so-far incurable brain diseases. The company was founded in 1999 and now has the single biggest team in the world dedicated exclusively to peptide vaccine development for treating Alzheimer's Disease. The work of the Axon team is regularly published in top-tier scientific journals and publications, including Lancet Neurology and Neurology.

Axon's lead vaccine AADvac1 is the most clinically-advanced tau therapy in development for treating and preventing Alzheimer's Disease. In late 2019, Axon successfully completed a Phase 2 clinical trial in almost 200 Alzheimer's patients, which revealed excellent safety, immunogenicity and efficacy. The evidence from its clinical trials on Alzheimer's disease proved its peptide-based vaccine platform to be very safe and well-tolerated. Over 80% of the treated Alzheimer's patients demonstrated an exceptional immune response and generated a robust quantity of antibodies. The therapy was able to significantly slow down the process of neurodegeneration in treated patients by almost 60%.

Axon's extensive knowledge in producing safe and immunogenic vaccines and well-established scalable technology allowed it to move very quickly in creating its novel peptide vaccine against COVID-19.

Note: Axon's share issue available through dedicated website (www.covidax.eu) is available to investors in a number of European countries under the European Prospectus Regulation. A complete list of approved Prospectus extracts for each of the selected countries is published on our website.

— The End —

George Salapa
AXON Neuroscience
media@axon-neuroscience.eu

SOURCE: AXON Neuroscience SE

ReleaseID: 618184

VALLETTA, MALTA / ACCESSWIRE / November 25, 2020 / The DeFi sector continues to see expansion in all aspects. According to recent reports, the market currently holds over $6 billion in value locked in smart contracts. Impressively, this growth is increasing in both its scope and rate. There are now more products, protocols, and platforms than ever in the market. This ever-growing diversity can make finding the best platforms a real choir.

At the current rate of entry, you would need to put aside some serious time and effort to get even the smallest grasp of the market. Complicating matters is the fact that there are new financial instruments being developed daily. These new systems provide more opportunity but also make understanding DeFi an ever-growing challenge.

Luckily, there are some DeFi projects that deserve your attention for their unique approach. These platforms introduce proprietary technologies and business models to eliminate some of the most pressing issues facing the market currently. From staking and lending for profits to eliminating centralization, DeFi is impressive. Here are 4 unique DeFi Projects to watch for the end of 2020

The Force Protocol

The Force Protocol is an add-on that works across the DeFi sector. This extra package for decentralized finance was designed to rectify some of the inherent issues developers and users encounter on the Ethereum network. Specifically, the Force Protocol streamlines contract upgrades, fixes data structure issues, removes slow on-chain interactions, and poor user experience due to a lack of necessary infrastructure.

The Force Protocol consists of a set of DeFi technical components and tokenized protocols that simplify the core functionalities of DeFi investing. The platform provides users with secure, inclusive, innovative, and transparent blockchain-based financial services. Additionally, the system introduces solutions for cross-platform transactions, stable coin issues, and on-chain payments

The Force Protocol relies on three DeFi technical components that all interact to accomplish the platform's goal. These components include fundamental components, extension components, and financial components. Together, these tools create a highly usable DeFi interface geared towards all user types.

Synthetix

Synthetix is a decentralized investment platform that brings new capabilities to the market. The platform's main characteristic is its ability to create Synths. Synths are on-chain representations of real-world assets. These synthetic versions of real-world assets can then be traded on a peer-to-peer basis.

This decentralized, non-custodial, multi-token infrastructure provides users with an impressive variety of DeFi protocols. Users can earn profits via staking, inflation, and fees. The SNX token makes it all possible. SNX is staked as collateral to potentially create any synthetic asset that resides on the platform. In this way, users can trade nearly anything from stocks like Tesla and Apple, to debt-equity on top of Ethereum.

Importantly, Synthetix recently partnered with Chainlink to ensure that its network provides the most up-to-date pricing metrics. ChainLink is another popular project that hosts a blockchain of oracles. Oracles are off-chain sensors that can send and receive data from a blockchain.

DeFi Yield Protocol (DYP)

The DeFi Yield Protocol (DYP) removes whale manipulation from the DeFi space forever. DYP takes care of this concern by integrating a DYP anti-manipulation feature that ensures that the rewards from supported tokens (DYP/ETH, DYP/USDC, DYP/USDT, and DYP/WBTC POOL) are automatically converted from DYP to ETH at 00.00 UTC. Also if the price of DYP is affected by more than -2.5 then the maximum DYP amount that does not affect the price will be swapped to ETH, with the remaining amount distributed in the next day rewards.

DYP Finance offers a utility token that enables users to interact with the features on the DYP smart contract. Ethereum miners can join the DYP mining pool and get rewarded monthly with a 10% bonus from the ETH monthly income earned by the pool. The automated Earn Vault will distribute 75% of profits to liquidity providers while the 25% left will be used to buy back their protocol token to add liquidity and maintain token price stability.

DYP features a decentralized governance protocol that helps the network to maintain a strong community of users engaged in the platform's development. Interestingly, the community gets to vote on whether to burn or reward users with the DYP tokens the anti-manipulation protocol secures. This level of community participation is one of the best aspects DeFi brings to the market.

NFTfi

NFTfi is a hybrid platform that takes the best aspects of DeFi and combines them with the growing value of the non-fungible token (NFTs) sector. NFTs are blockchain verifiable collectors. The most popular form of NFT is ERC-721 tokens. Examples of valuable NFTs include tokens from Gods Unchained, Decentraland, Cryptovoxels, and Cryptokitties. These tokens are also what's used to verify digital artwork.

Users can stake their NFTS and receive loans using NFTs as collateral. This strategy allows anyone who owns inactive or unused digital assets to use them to get short term crypto loans. When users repay this loan with interest, their NFT is unlocked.

Lenders can browse through the selection of NFTs available at any time. Once they find an NFT they are willing to lend against the process is simple. They select the amount they are willing to lend and make an offer to the borrower. If the offer is accepted, the NFT gets locked in a smart contract. If the borrower is unable to repay the loan, the lender gets to keep the NFT.

4 Unique DeFi Projects to Watch for the End of 2020

The rise of DeFi introduces some new and exciting ways to earn free crypto. The key to success is to only stick with reputable platforms like the ones listed above and you are sure to achieve your desired ROIs. DeFi may be new, but the profits its producing are enough to motivate continued adoption for years to come. As the year starts to close out, there's no reason to slack on your investment strategy.

Contact:

Teki Kolaneci – Digital Strategy Manager
Company: DYP FInance
Address: Malta, Valeta
Phone: 07355050442
Email: contact@dyp.finance
Website: https://dyp.finance

SOURCE: DYP Finance

ReleaseID: 618345

GEORGE TOWN, GRAND CAYMAN / ACCESSWIRE / November 25, 2020 / Orion Terminal, the first decentralized gateway to the entire cryptocurrency market, is preparing for a major milestone with the first phase of its public mainnet scheduled to launch on December 15.

By seamlessly aggregating liquidity from all major centralized and decentralized exchanges and swap pools into a single orderbook, Orion Terminal offers traders a simple, convenient gateway to trading and eliminates the need to surrender their private keys.

Orion Protocol's ecosystem is built on a network of brokers running Orion Broker Software with accounts across multiple exchanges (or exchanges themselves, including BitMax, KuCoin, MXC, Injective Protocol, and others).In recent months, the defi platform has conducted rigorous testing among a closed group of brokers on their private main net in a bid to ensure smooth functionality and robust security. CertiK, a leading security firm, has also audited the Orion Terminal mainnet in advance and confirmed its stability.

Platform updates will be continually rolled out over the month following the launch of Orion Terminal. Meanwhile, Orion Protocol has ambitious plans for the terminal in 2021, expanding its offering into lending, margin trading, leveraged ETFs, derivatives, contract trading, NFTs, and staking of any asset type. Staking of Orion Protocol's native ORN token will be available on the platform in early Q1.

At the core of Orion Protocol is its native ORN token, providing holder benefits such as discounted trading, advanced features, protocol access, and staking returns.

"The launch of Orion Terminal's mainnet has been a vision of ours since Orion Protocol's inception in 2018, and we're ecstatic that we're almost here " says Alexey Koloskov, Chief Executive Officer of Orion Protocol.

"Having spent several years developing the protocol, we're incredibly excited to take our first step towards revolutionizing trading. . Users will be able to trade with the liquidity of the entire crypto market in one place, while the aggregated order books of every exchange in market will guarantee the best price, every time, with almost zero spread and zero slippage across thousands of trading pairs. Best of all, users have access to all of this and more without the need to ever give up their private keys, trading directly from their wallet."

About Orion Protocol

Built on the most advanced liquidity aggregator ever developed, Orion Protocol aggregates the liquidity of every single crypto exchange into one platform: providing a decentralized gateway to the entire digital asset market. In doing so, Orion is building a protocol on which to bridge the worlds of crypto, traditional finance, and real world assets.

Media Contact

Tal Harel, MarketAcross
Tal@MarketAcross.com

SOURCE: Orion Protocol

ReleaseID: 618343

VANCOUVER, BC / ACCESSWIRE / November 25, 2020 / EMPOWER CLINICS INC. (CSE:CBDT) (OTC PINK:EPWCF) (Frankfurt:8EC) ("Empower" or the "Company") has filed today its unaudited condensed interim financial statements and related management's discussion and analysis, both of which are available at www.SEDAR.com. All financial information in this press release is reported in United States dollars, unless otherwise indicated.

"Our Q3 2020 performance overall exceeded our expectations given the challenging operating environment in our key markets, yet the team managed to serve large quantities of patients while maintaining strict COVID-19 protocols for health and safety." Said Steven McAuley, Chairman and CEO. "We also continue to implement numerous business development opportunities setting the stage for an exciting Q4 and 2021."

Q3 2020 Highlights

5,044 patient visits generating total revenue of $629,854, compared to 5,807 patient visits generating $663,003 for Q3 2019.
Net loss of $460,035 or $0.00 per share, compared to a loss of $504,532 or $0.00 per share for Q3 2019, driven by increases in direct clinic costs as a percentage of revenue. This issue was addressed subsequent to the quarter by changing the compensation structure of the clinic's physicians along with the implementation of further cost cutting measures in Arizona clinics.
Cash used in operating activities was $534,141, compared to $487,720 for Q3 2019.
Cash at September 30, 2020 of $112,539, compared to cash of $179,153 at December 31, 2019.

YTD 2020 Highlights

17,457 patient visits generating total revenue of $2,306,111, compared to 11,304 patient visits generating $1,409,143 for nine months ended September 30, 2019.
Net loss of $1,380,316 or $0.01 per share, compared to a loss of $2,359,579 or $0.02 per share for nine months ended September 30, 2019, driven by year to date increased profitability related to the Sun Valley Health acquisition and robust reductions in salaries and benefits, legal and professional fees and non-cash share-based payments expense.
Cash used in operating activities was $531,494, compared to cash used in operating activities of $1,819,670 for nine months end September 30, 2019.

Financial Summary

$, except where noted

Three months ended September 30,

Nine months ended September 30,

2020

2019

2020

2019

Patient visits (#)

5,044

5,807

17,457

11,304

Clinic Revenues

629,854

663,003

2,306,111

1,409,143

Direct Clinic Expenses

246,317

55,397

758,622

177,560

Loss from operations

(844,357)

(843,897)

(1,402,803)

(2,545,005)

Net loss

(460,035)

(504,532)

(1,380,316)

(2,359,579)

Net loss per share

(0.00)

(0.00)

(0.01)

(0.02)

Financial Performance for the nine months ended September 30, 2020

Increase in clinic revenues – The increase is attributed to the acquisition of Sun Valley in 2019 and the addition of 5 clinics for the full reporting period.

Increase in direct clinic expenses – This increase above prior year is attributable to the increase in number of patient visits and the related physician costs.

Decrease in loss from operations – This decrease in net loss from operations primarily attributable to an increase in clinic profitability with the acquisition of Sun Valley and a decrease in salaries and benefits, legal and professional fees and non-cash share-based payments expense.

Loss from operations for the quarter – The loss for the quarter is comparable to the loss for the same quarter in 2019. While able to reduce legal and professional fees for the quarter, there was an increase in direct clinic costs. This issue was addressed subsequent to the quarter by changing the compensation structure of the clinic's physicians.

Please refer to the Company's unaudited condensed interim consolidated financial statements for the three and nine months ended September 30, 2020 and 2019, and accompanying Management Discussion and Analysis for a full review of the operations.

About Empower

Empower is creating a network of physicians and practitioners who integrate to serve patient needs, in-clinic, through telemedicine, and with decentralized mobile delivery. A simplified, streamlined care model bringing key attributes of the healthcare supply chain together, always focused on patient experience. The Company provides COVID-19 testing services to consumers and businesses as part of a four-phased nationwide testing initiative in the United States. Empower recently acquired Kai Medical Laboratory, LLC as a wholly owned subsidiary with large-scale testing capability.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Dustin Klein
Director
dustin@svmmjcc.com
720-352-1398

Investors: Steven McAuley
CEO
s.mcauley@empowerclinics.com
604-789-2146

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain "forward-looking statements" or "forward-looking information" (collectively "forward looking statements") within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as "plans", "continues", "expects", "projects", "intends", "believes", "anticipates", "estimates", "may", "will", "potential", "proposed" and other similar words, or information that certain events or conditions "may" or "will" occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the acquisition of Kai Medical Laboratory; the fact that Kai Medical Laboratory will complete the development of ABC RT-PCR test; the development of new accounts using the new test; the transaction terms; the expected number of clinics and patients following the closing; the future potential success of Kai Medical Laboratory, Sun Valley's franchise model; the anticipated date of closing of the acquisition and the occurrence thereof; and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2020 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Kai Medical Laboratory acquisition may not be completed on the terms expected or at all; that the Company's products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse affect on the Company's business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company's control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: Empower Clinics Inc.

ReleaseID: 618332

VANCOUVER, BC / ACCESSWIRE / November 25, 2020 / Ximen Mining Corp. (TSXV:XIM)(FRA:1XMA)(OTCQB:XXMMF) (the "Company" or "Ximen") is pleased to announce that it has completed its portal construction at the Kenville Gold Mine project in the Nelson mining camp in southern British Columbia.

The installation of the new portal culvert is now complete, providing access to the Kenville mine 257 level. The final stages included placement of back-fill, construction of a door on the outside of the culvert, an as-built survey, and installation of rail ties and track on the inside to connect with the 257 mine level (see photos below).

Photo of CEO Christopher Anderson hammering in the "Golden Spike" connecting the new underground rail with the Kenville 257 Level rail line.

Permitting for the new mine development is progressing well with public notifications and responses completed. The final application has been submitted to the Mines Review Committee.

Dr. Mathew Ball, P.Geo., VP Exploration for Ximen Mining Corp. and a Qualified Person as defined by NI 43-101, approved the technical information contained in this News Release.

The Company also announces that it has closed a financing for gross proceeds of $250,000. The non-brokered private placement consisted of 694,444 units at a price of $0.36 per unit. Each Unit consists of one common share and one transferable common share purchase warrant. Each whole warrant will entitle the holder to purchase, for a period of 36 months from the date of issue, one additional common share of the Issuer at an exercise price of $0.60 per share. The hold expiry date for this placement is March 11, 2021.

Further the Company announces that it has closed a non-brokered private placement consisting of 595,240 flow through shares at a price of $0.42 per share for gross proceeds of $250,000. Each Flow-Through share consists of one common share that qualifies as a "flow-through share" as defined in subsection 66(15) of the Income Tax Act.

The Company paid a cash commission of $17,500 and issued 41,666 finders warrants to Qwest Investment Fund Management Ltd. The finder warrants are valid for 2 years from closing with an exercise price of $0.42. All securities issued in connection with the flow through offering will be subject to a hold period expiring March 17, 2021.

The net proceeds from the private placements will be used for the further exploration on the Company's British Columbia mineral properties and general working capital.

On behalf of the Board of Directors,

"Christopher R. Anderson"

Christopher R. Anderson,
President, CEO and Director
604 488-3900

Investor Relations:
Sophy Cesar,
604-488-3900,
ir@XimenMiningCorp.com

About Ximen Mining Corp.

Ximen Mining Corp. owns 100% interest in three of its precious metal projects located in southern BC. Ximen`s two Gold projects The Amelia Gold Mine and The Brett Epithermal Gold Project. Ximen also owns the Treasure Mountain Silver Project adjacent to the past producing Huldra Silver Mine. Currently, the Treasure Mountain Silver Project is under a option agreement. The option partner is making annual staged cash and stocks payments as well as funding the development of the project. The company has recently acquired control of the Kenville Gold mine near Nelson British Columbia which comes with surface and underground rights, buildings and equipment.

Ximen is a publicly listed company trading on the TSX Venture Exchange under the symbol XIM, in the USA under the symbol XXMMF, and in Frankfurt, Munich, and Berlin Stock Exchanges in Germany under the symbol 1XMA and WKN with the number as A2JBKL.

This press release contains certain "forward-looking statements" within the meaning of Canadian securities This press release contains certain "forward-looking statements" within the meaning of Canadian securities legislation, including statements regarding the receipt of TSX Venture Exchange approval and the exercise of the Option by Ximen. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are statements that are not historical facts; they are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "aims," "potential," "goal," "objective," "prospective," and similar expressions, or that events or conditions "will," "would," "may," "can," "could" or "should" occur, or are those statements, which, by their nature, refer to future events. The Company cautions that forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made and they involve a number of risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Except to the extent required by applicable securities laws and the policies of the TSX Venture Exchange, the Company undertakes no obligation to update these forward-looking statements if management's beliefs, estimates or opinions, or other factors, should change. Factors that could cause future results to differ materially from those anticipated in these forward-looking statements include the possibility that the TSX Venture Exchange may not accept the proposed transaction in a timely manner, if at all. The reader is urged to refer to the Company's reports, publicly available through the Canadian Securities Administrators' System for Electronic Document Analysis and Retrieval (SEDAR) at www.sedar.com for a more complete discussion of such risk factors and their potential effects.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any state in the United States in which such offer, solicitation or sale would be unlawful.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Ximen Mining Corp.

ReleaseID: 618329

VANCOUVER, BC / ACCESSWIRE / November 25, 2020 / iMetal Resources Inc. (TSXV:IMR)(OTCBB:ADTFF)(FRANKFURT:A7V2) ("iMetal" or the "Company") is pleased to announce that R. Timothy Henneberry, P. Geo., has been appointed to the Board of Directors effective immediately. Mr. Henneberry has been assisting management for the past few months with a technical review of the Company's existing project portfolio and has been focused on the identification of priority drilling targets.

Mr. Henneberry's appointment follows the resignations of Ruth Bezys and Mark Fedikow, who have stepped down as directors to focus on other ventures. Ms. Bezys and Mr. Fedikow will remain with the Company in a consulting capacity for the next twelve months. In connection with the appointment of Mr. Henneberry, the Board of Directors has also appointed Saf Dhillon as Chief Executive Officer of the Company, and Johan Grandin as Vice-President of Business Development.

"I've personally known Tim and have had a great working relationship with him over the past 15 years. He's an excellent geologist who also understands the overall big picture. Tim's background will be a positive driving force at the corporate level and his extensive experience can help interpret our data to minimize our drilling risk", says Saf Dhillon, Chief Executive Officer.

R. Timothy Henneberry

Mr. Henneberry, a Dalhousie University graduate, is a Professional Geoscientist registered in British Columbia with over 40 years of experience in domestic and international exploration and production for base and precious metals and industrial minerals.

He was a founding Director, President and Chief Executive Officer of First Vanadium Corp. from 2006 to 2011, founding Director, President and Chief Executive Officer of Indigo Exploration Inc. from 2009 to 2011 and a founding Director, President and Chief Executive Officer of Carebook Technologies Inc. from 2018 to 2020. He was a former Director and Interim Chief Executive Officer of Arcwest Exploration Inc. and a former Director of Broadway Gold Mining Ltd.

Currently, Mr. Henneberry serves as Chief Executive Officer and a Director of Golden Independence Mining Corp., a Director of Raindrop Ventures Inc. and a Director of Silver Sands Resources Corp. He sits on the Advisory Boards of Max Resource Corp., Resolve Ventures Corp. and Universal Copper Ltd.

About iMetal Resources Inc.

A Canadian based junior exploration company focused on the exploration and development of its portfolio of resource properties in Ontario and Quebec. iMetal is focused on advancing its Gowganda West Project that borders the Juby Project, an advanced exploration-stage gold project located within the Shining Tree area in the southern part of the Abitibi greenstone belt about 100 km south-southeast of the Timmins gold camp.

ON BEHALF OF THE BOARD OF DIRECTORS,

Saf Dhillon
Chief Executive Officer
iMetal Resources Inc.
saf@imetalresources.ca
Tel. (604-484-3031)
Suite 510, 580 Hornby Street, Vancouver, British Columbia, V6C 3B6.
https://imetalresources.ca

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

SOURCE: iMetal Resources, Inc.

ReleaseID: 618293

World Artists United Who Produces the Music Entrepreneur Conference Coming Up on December 11 and 12th 2020 Is Partnering With the Music Fund to Provide Up to $500,000 to Artists and Labels

NEW ORLEANS, LA AND NEW YORK, NY / ACCESSWIRE / November 24, 2020 / Yet another key leader in music who puts serious cash in the hands of rising artists and music-rights holders has been added to the Music Entrepreneur family.

Over the years, the conference has been bringing together business leaders and personal development professionals who know what it takes to build strong brands, connected teams and growth strategies that allow music entrepreneurs to break barriers and develop sustainable careers.

"One challenge we always seemed to face was in finding financial resources for growth," says Rachel Karry, the co-founder of Music Entrepreneur. "If you don't want to sign to a label, give control to an investor and don't have a wealthy aunt willing to cut you a check for your crazy dream, there seem to be few financial options to move your career forward. We dreamt of a "music bank" our community could tap into. And then we found The Music Fund! We now have over $500,000 for creators to get to the next level."

The Music Fund provides an automated platform that uses a data-driven smart-pricing algorithm to offer up-front cash for a portion of any artist's royalty stream income. The founders behind the company created an investment fund that allows investors to help rising artists meet their needs in an artist-first and scalable way. The company is breaking down the artist-funding hurdle by solving multiple financing headaches associated with the delay in accessing income generated from streaming.

Rights holders stay in control of their future. Once The Music Fund makes them an offer, they decide what percentage of their music royalties they feel comfortable sharing. Based on the streaming data acquired over the last two years, The Music Fund offers up to $50,000 per deal. Rights holders receive cash simply by sharing one percent or more of their master-royalty earnings, and after two years, 100% of the rights holders' ownership is given back and the deal is over. No one owns an artist's hard work but them!

The Music Fund recommends that artists who apply have a minimum of 100,000 monthly streaming-service listeners, but those with as few at 10,000 are encouraged to apply and find out how much money they are eligible for. Funding is available to artists, producers, indie labels, managers and anyone else who has streaming royalties, and can be offered in as little as one day. Test the company's payment-calculation formula via Playground and see how it works at www.TheMusic.fund

"What we really love about TMF is that they are the first company to put their money where their mouth is" says Karry. Once The Music Fund sends money to someone, they won't ask for even $1 back regardless of how much they end up collecting over the two-year period. It's not like a label advance with loopholes where an artist is on the hook to pay back an advance or required to create music they won't own. If TMF doesn't make a return on their investment, it's their loss. TMF is also only tapping into the back catalogue, so artists can create more music for the future and own 100% of it. "This is a key component in building the future of the music industry," says Karry. "The days when artists had little creative control and kept a mere 15% ownership of their own music are over."

"By making a large number of small bets we simply hope we get it right on average, and the artist wouldn't be on the hook if we get it wrong," says John Funge, Founder and CEO of The Music Fund. "As we test out this new approach to support music entrepreneurs, we are committed to being socially responsible and creating a model that helps creators self-direct their career."

Let's say someone gets to put cash in their pocket, then what? Music Entrepreneur and its parent company World Artists United are putting simple solutions and industry pros at the fingertips of these creative entrepreneurs to guide them in making the most of that money. "We've been building partnerships around the world with the brightest business leaders and tech innovators in music, from those building next-level websites that allow artists to efficiently grow and track their fanbase, to marketing experts who can help them release their next single like a pro, and ecommerce rock stars who will help them generate sales," says Karry.

The Music Fund isn't stopping there, however, by partnering with Oasis Labs, a pioneering privacy paradigm that protects and keeps music data anonymous, the fund has created a privacy-first framework that will allow artists to take control of their own data (including Spotify streaming data, royalty earnings data, social media stats, and data from Facebook ads) and choose how and who to safely share it with. Artists will be able to securely upload their data to the data-sharing platform built on top of Oasis Labs' privacy-preserving blockchain and selectively grant access to companies that provide services they are interested in. Artists will be able to see who is accessing their data and revoke access at any time.

For everyone who applies, MEcon will also be providing a complimentary ticket to the conference and hosting special workshops, courses and mastermind groups that take music marketing and business development strategy to the next level.

To apply for funding, visit themusic.fund/WAU and receive an extra $50 with your offer.

Learn more about Music Entrepreneur at www.musicentrepreneurconference.com

And, World Artists United at www.Worldartistsunited.com

Contact Info:
Name: Kwasi Asare
Email: Send Email
Organization: World Artists United
Address: 838 North Rampart Street, New Orleans, Louisiana 70116, United States
Website: https://www.worldartistsunited.com/

SOURCE: World Artists United

ReleaseID: 618327

NEW YORK, NY / ACCESSWIRE / November 24, 2020 / Real estate is one of the busiest scenes in the world. Experts and professionals in the industry have to keep up with trends to have the upper hand. Bòunyadej Q. Sànanikone is one of the most well-versed real estate sales professionals and has taken his skills from his native country of Laos to New York City in the United States to improve the real estate market in his way.

Bòunyadej Sànanikone comes from an influential political and real estate family. Like many others in his family, he chose to pursue a different path by following a real estate career and set himself apart while at it. His great-grandfather, Phoui Sànanikone, is the first Laotian Politician to have held multiple positions from Prime Ministership to Foreign Affairs Minister. The legendary Sànanikone family is often referred to as the Rockefellers and the Kennedys of Laos. They are having to own various businesses stemming from pharmaceuticals, aerospace, and real estate.

The name Sànanikone is a well-respected name in Asia. While Mr. Sànanikone may not be pursuing a political career, he is carrying on the family name by excelling in a field that everyone in the world is connected to.

(1959 Press Photo UN Secretary-General Dag Hammarskjold (right) with His Excellency Prime Minister Phoui Sananikone (left).

Mr. Sànanikone has a strong background in risk-adjustment investments as a licensed, accredited investment professional from Adagio Group. He is also an expert luxury real estate marketer with modern marketing skills and access to analytical data. The blandness and boringness informed his move to New York real estate. In his words, "There isn't a broker in this city that can harness the power of basic analytics coupled with alternative marketing toward buyers and viewers. I want to make real estate buying decisions fun and exciting. I compose real estate analytics into a fun and modern understanding of marketing."

He started his career at The Norasing Group, a firm owned by his maternal grandfather. At the firm, Sànanikone completed more than ten OHDACA government-projects, and now all that expertise is being pumped into his real estate team in New York, The Sananikone Group NYC.

Sànanikone's goal is to make real estate buying decisions a lot easier and more fun for the players. His ability to blend traditional finance and complex risk-adjusted returns to make purchases happen and go smoothly is one of the rarest skills in the industry. With his team, he translates raw data and risk-adjusted return metrics to amaze buyers, strike a connection, and get them to buy.

He has more than 30,000 followers on social media through which he targets and markets to real estate developers, sales teams, and brokerages. Making sales happen is his specialty, and he plans to grow his team to the point where he handles the highest volume of real estate transactions in New York. "I will become the #1 Real Estate Broker and have the #1 real estate sales team in New York City. I am an expert at marketing new development residential properties and private clients who want to sell their properties."

Through his team, the Sananikone Group NYC, Bòunyadej Q. Sànanikone aims to change the way real estate marketing is done while also giving buyers a new approach to making decisions.

Learn more about Bòunyadej Q. Sànanikone on his Instagram page.

Company: The Sananikone Group NYC
Office Number: (212)-220-6030
Email: q@sananikonegroup.com
Website:https://www.instagram.com/bounyadej/

SOURCE: The Sananikone Group NYC

ReleaseID: 618320

VANCOUVER, BC / ACCESSWIRE / November 25, 2020 / AZARGA URANIUM CORP. (TSX:AZZ)(OTCQB:AZZUF)(FRA:P8AA) ("Azarga Uranium" or the "Company") is pleased to announce that the United States Environmental Protection Agency (the "EPA") has issued the final permits for the Company's Class III and Class V Underground Injection Control activities (the "EPA Permits") at its primary development project, the Dewey Burdock in-situ recovery uranium project in South Dakota, USA (the "Dewey Burdock Project").

Blake Steele, President and CEO stated: "This critical milestone significantly de-risks our flagship asset, the advanced stage, low-cost Dewey Burdock Project, and moves the Company substantially closer to becoming the next uranium producer in the USA. Issuance of the EPA Permits follows the agency's extensive review of the Dewey Burdock Project and reaffirms the findings of the United States Nuclear Regulatory Commission (the "NRC") that the project is both technically and environmentally sound. With pivotal federal permits now issued by both the EPA and NRC, the Company is in a strong position to finalize the state permitting process, where the South Dakota Department of Environment and Natural Resources (the "DENR") staff have already recommended approval of the key state permits."

Steele further noted: "At a time when the uranium market remains in a structural deficit and the United States government has shown historic bi-partisan support for the uranium sector, as evidenced by the Senate Committee on Appropriations draft fiscal year 2021 funding measures and subcommittee allocations' inclusion of US$150 million for a United States uranium reserve, Azarga Uranium continues to unlock the value of one of the preeminent undeveloped in-situ recovery uranium projects in the USA."

The EPA Permits represent the second of three major regulatory agency approvals, and the final key federal agency approval, required for the Dewey Burdock Project. The NRC has already issued the Company's Source and Byproduct Materials License. The third and remaining major regulatory agency approval is required by the South Dakota DENR, whose staff have already recommended the approval of the key state permits. Board hearings to finalize the key state permits were deferred until the federal permits, namely those pertaining to the NRC and EPA, were issued. With both the NRC and EPA Permits now issued, the Company will recommence the state permitting process imminently.

About Azarga Uranium Corp.

Azarga Uranium is an integrated uranium exploration and development company that controls ten uranium projects and prospects in the United States of America ("USA") (South Dakota, Wyoming, Utah and Colorado), with a primary focus of developing in-situ recovery uranium projects.

For more information please visit www.azargauranium.com.

Follow us on Twitter at @AzargaUranium.

For further information, please contact:

Blake Steele, President and CEO
+1 303 790-7528
E-mail: info@azargauranium.com

Disclaimer for Forward-Looking Information

Certain information and statements in this news release may be considered forward-looking information or forward-looking statements for purposes of applicable securities laws (collectively, "forward-looking statements"), which reflect the expectations of management regarding its disclosure and amendments thereto. Forward-looking statements consist of information or statements that are not purely historical, including any information or statements regarding beliefs, plans, expectations or intentions regarding the future. Such information or statements may include, but are not limited to, statements with respect to the EPA Permits moving the Company substantially closer to becoming the next uranium producer in the USA, the Company being in a strong position to finalize the state permitting process with the pivotal federal permits now issued by both the EPA and NRC, the United States government showing historic bi-partisan support for the uranium sector, as evidenced by the Senate Committee on Appropriations draft fiscal year 2021 funding measures and subcommittee allocations' inclusion of US$150 million for a United States uranium reserve, Azarga Uranium continuing to unlock the value of one of the preeminent undeveloped in-situ recovery uranium projects in the USA, the third and remaining major regulatory agency approval is required by the South Dakota DENR, whose staff have already recommended the approval of the key state permits and the Company anticipating recommencing the state permitting process imminently. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits Azarga Uranium will obtain from them. These forward-looking statements reflect management's current views and are based on certain expectations, estimates and assumptions, which may prove to be incorrect. A number of risks and uncertainties could cause actual results to differ materially from those expressed or implied by the forward-looking statements, including without limitation: the risk that the Company does not become the next uranium producer in the USA, the risk that the Company is not in a strong position to finalize the state permitting process with the pivotal federal permits now issued by both the EPA and NRC, the risk that the final EPA Permits are appealed, the risk that the final EPA Permits are appealed and this delays the state permitting process, the risk that the United States government does not approve the Senate Committee on Appropriations draft fiscal year 2021 funding measures and subcommittee allocations' inclusion of US$150 million for a United States uranium reserve, the risk that Azarga Uranium does not continue to unlock the value of the Dewey Burdock Project, the risk that the third and remaining major regulatory agency approval required by the South Dakota DENR is not issued for the key state permits, the risk that the Company does not recommence the state permitting process imminently or at all, the risk that such statements may prove to be inaccurate and other factors beyond the Company's control. These forward-looking statements are made as of the date of this news release and, except as required by applicable securities laws, Azarga Uranium assumes no obligation to update these forward-looking statements, or to update the reasons why actual results differed from those projected in the forward-looking statements. Additional information about these and other assumptions, risks and uncertainties are set out in the "Risks and Uncertainties" section in the most recent AIF filed with Canadian security regulators.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this News Release.

SOURCE: Azarga Uranium Corp.

ReleaseID: 618322